HSDD Field To Itself, BioSante Has High Hopes For LibiGel
This article was originally published in The Pink Sheet Daily
Company thinks gel formulation, Special Protocol Assessment with FDA improve its chances for success.
You may also be interested in...
New, Existing Players See Opportunity In Crowded Contraceptive Space
With the notable exceptions of Bayer and Johnson & Johnson, big pharma generally does not participate in the contraceptive market. (Merck and Pfizer also are in the market, although their participation occurs on a smaller scale and largely outside the U.S.)
BI Drops Flibanserin; BioSante Gets Excited
Boehringer Ingelheim shuts down development of its female desire drug due to complications in the regulatory process.